Indus Gas FY2025 results: sharp impairment, contract uncertainty, and a swing to loss
Indus Gas has posted audited results for the 12 months to 31 March 2025, and the headline is stark: a large, non-cash asset impairment pushed the Group to a big statutory loss despite posting an operating profit. The other big theme is contract risk – both the Production Sharing Contract (PSC) and the Gas Sales and Purchase Agreement (GSPA) have expired, with sales continuing under an interim term sheet while arbitration with the sole customer, GAIL, rumbles on.
Here are the numbers and why they matter for investors.
Key figures investors should know
| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | US$ 29,651,641 | US$ 42,930,441 |
| Operating profit | US$ 26,382,299 | US$ 36,555,535 |
| Profit before tax | US$ 26,385,262 | US$ 36,120,698 |
| (Loss)/Profit after tax | (US$ 357,576,415) | US$ 20,184,525 |
| Impairment of PPE | US$ 533,851,051 | Not applicable |
| Property, plant & equipment (carrying value) | US$ 776,139,979 | US$ 1,291,623,066 |
| Cash and cash equivalents | US$ 240,220 | US$ 2,069,244 |
| Bonds outstanding | US$ 164,087,347 | US$ 164,026,896 |
| Current payable to related parties | US$ 709,604,109 | US$ 12,656 |
| Gearing ratio | 99.32% | 74.26% |
| Basic EPS | (1.95) | 0.11 |
US$ 533.9 million impairment: what it is and why it matters
The Group recognised a US$ 533,851,051 impairment against production, plant and equipment, cutting the carrying value down to US$ 776,139,979. This was driven by IAS 36 testing after several “trigger” events: expiry of the PSC and GSPA, declining production, reservoir challenges, and ongoing arbitration with GAIL. An independent valuer’s work and updated cash flow estimates underpinned the decision.
Why this matters: impairments are non-cash, but they signal lower expected future cash flows from the Block. It also reduces balance sheet equity sharply – retained earnings flipped to a retained loss of US$ 54,557,477. A deferred tax credit of US$ 160,142,858 softened, but did not offset, the impact.
PSC and GSPA expired: interim sales continue, but going concern flagged
Two key commercial pillars have lapsed:
- PSC expired on 20 August 2024 – extension has been applied for but is not yet granted.
- GSPA with GAIL expired on 30 September 2024 – sales continue under an Interim Term Sheet, now extended to 31 January 2026.
On top, GAIL has initiated arbitration. Indus recognised income from the expiry of GAIL’s make-up gas rights, writing off deferred revenue of US$ 25,470,135. The Board, backed by legal advice, does not expect an outflow and has booked no provision.
The auditor issued an unmodified opinion but highlighted a Material Uncertainty related to Going Concern due to the expired PSC/GSPA and reliance on interim arrangements. That does not mean failure is expected – but it is a clear risk flag until long-term agreements are secured.
Balance sheet: liquidity is tight and funding is concentrated
Cash at year-end was just US$ 240,220, with current assets of US$ 117,017,033 largely made up of receivables from a related party (US$ 109,239,970). Current liabilities ballooned to US$ 725,965,743, almost entirely due to reclassifying the shareholder loan from Gynia Holdings to current (US$ 709,560,347) because it is repayable on demand.
Important mitigant: Gynia has confirmed it will not recall the on-demand loan within 12 months. All secured bank loans were repaid on time, and bonds of US$ 164,087,347 remain due in 2027. Still, the gearing ratio at 99.32% and very low cash are clear pressure points. The going concern note also references continued shareholder support and internal cash generation to meet obligations.
Operations and pricing: revenues down, capex lower, prices regulated
Revenue fell to US$ 29.65 million (2023-24: US$ 42.93 million), reflecting reduced output and operational constraints. Production volumes themselves are not disclosed. Operating profit was US$ 26.38 million, showing the asset can still throw off operating cash before financing and exceptional items.
Capex slowed sharply: net investments into property, plant and equipment were US$ 18.37 million (2023-24: US$ 70.96 million), with US$ 13,465,472 of borrowing costs capitalised at a 6.80% average rate. Gas prices are tied to India’s domestic formula – 10% of the monthly average Indian crude basket – and ranged from US$ 8.90 to US$ 7.29 per MMBTU during the year.
What to watch next: catalysts and risks
- PSC extension – cornerstone for investment planning and reserves monetisation. Timeline not disclosed.
- Long-term GSPA – interim terms now run to 31 January 2026. A renewed long-term contract would de-risk cash flows.
- Arbitration outcome with GAIL – management expects no outflow; resolution expected to be protracted. No provision booked.
- Liquidity – cash is low; reliance on majority shareholder support remains high. Any movement in related-party balances will be key.
- Production trajectory – volumes not disclosed. Any stabilisation or uplift would support revenue recovery.
- India gas price formula – pricing is linked to the crude basket and can move monthly. Sensitivity to price and discount rate is highlighted in the impairment testing.
Why this matters for shareholders
This set of results is dominated by accounting reality catching up with commercial uncertainty. The impairment reduces reported asset value and equity, pushing the Group into a statutory loss despite an underlying operating profit. The auditor’s material uncertainty flag underlines that the PSC/GSPA expiries are not just footnotes; they are central to the investment case.
On the positive side, gas continues to flow to GAIL under the interim term sheet, all bank loans were repaid on time, and the shareholder has reaffirmed support for at least the next 12 months. India’s policy push for domestic gas and the regulated pricing mechanism offer a macro tailwind, albeit not a panacea for operational or contractual issues.
My take: high-risk, contract-led story until visibility improves
Short term, this is a contract and balance sheet story more than a production growth story. The key swing factors are the PSC extension and a long-term GSPA with GAIL. Secure those, and the heavy impairment could prove to be a reset that clears the decks. Fail to secure them, and the going concern risks remain front and centre.
For risk-tolerant investors, the watchlist is simple: PSC/GSPA progress, arbitration updates, liquidity movements, and any colour on production stabilisation. For everyone else, it is reasonable to wait for contract clarity to reduce the binary risk profile. No dividend is proposed, and the Group remains tightly geared, so capital discipline and stakeholder negotiations are pivotal from here.
